ebglyss
almirall, s.a. - lebrikizumab - dermatitis, atopisch - andere dermatologische präparate - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
fasenra injektionslösung
astrazeneca ag - benralizumabum - injektionslösung - benralizumabum 30 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 1 ml. - schweres eosinophiles asthma - biotechnologika
fasenra pen 30 mg /1 ml lnjektionslösung
astrazeneca ag - benralizumabum - lnjektionslösung - benralizumabum 30 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - schweres eosinophiles asthma - biotechnologika
hemlibra 30mg/1ml injektionslösung
roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 30 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 1 ml. - hämophilie a - biotechnologika
hemlibra 60mg/0.4ml injektionslösung
roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 60 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 0.4 ml. - hämophilie a - biotechnologika
hemlibra 105mg/0.7ml injektionslösung
roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 105 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 0.7 ml. - hämophilie a - biotechnologika
hemlibra 150mg/1ml injektionslösung
roche pharma (schweiz) ag - emicizumabum - injektionslösung - emicizumabum 150 mg, histidinum, acidum asparticum ad ph, argininum, poloxamerum 188, aqua ad iniectabile ad solutionem pro 1 ml. - hämophilie a - biotechnologika
omvoh
eli lilly nederland b.v. - mirikizumab - colitis, ulzerativ - immunsuppressiva - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.
fasenra
astrazeneca ab - benralizumab - asthma - medikamente für obstruktive atemwegserkrankungen, - fasenra ist angezeigt als add-on erhaltungstherapie bei erwachsenen patienten mit schwerem eosinophilen asthma nicht ausreichend kontrolliert, trotz hoher dosis, inhalative corticosteroide plus langwirksame β-agonisten.
hemlibra
roche registration limited - emicizumab - hämophilie a - antihämorrhagika - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra kann verwendet werden in allen altersgruppen.